Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study

SIMPLE SUMMARY: The introduction of BRAF/MEK-directed targeted therapy (TT) has significantly improved the management of patients with advanced BRAF-V600-mutant melanoma. Although resistance occurs, there is a subgroup of patients showing a complete response (CR) to TT and who maintain durable disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Stege, Henner, Haist, Maximilian, Schultheis, Michael, Fleischer, Maria Isabel, Mohr, Peter, Meier, Friedegund, Schadendorf, Dirk, Ugurel, Selma, Livingstone, Elisabeth, Zimmer, Lisa, Herbst, Rudolf, Pföhler, Claudia, Kähler, Katharina, Weichenthal, Michael, Terheyden, Patrick, Nashan, Dorothée, Debus, Dirk, Kaatz, Martin, Ziller, Fabian, Haferkamp, Sebastian, Forschner, Andrea, Leiter, Ulrike, Kreuter, Alexander, Ulrich, Jens, Kleemann, Johannes, Bradfisch, Fabienne, Grabbe, Stephan, Loquai, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151093/
https://www.ncbi.nlm.nih.gov/pubmed/34065877
http://dx.doi.org/10.3390/cancers13102312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151093/
https://www.ncbi.nlm.nih.gov/pubmed/34065877
http://dx.doi.org/10.3390/cancers13102312

Ejemplares similares